Frederic Reu
About Frederic Reu
Frederic Reu serves as the Vice President of Early Clinical Development at Deciphera Pharmaceuticals, a position he has held since 2021. He has extensive experience in oncology and internal medicine, having worked in various academic and clinical roles across the United States and Germany.
Work at Deciphera Pharmaceuticals
Frederic Reu serves as the Vice President of Early Clinical Development at Deciphera Pharmaceuticals. He has held this position since 2021, contributing to the company's focus on developing innovative therapies for cancer treatment. Deciphera Pharmaceuticals is located in Waltham, Massachusetts, and is known for its commitment to advancing cancer care through targeted therapies.
Previous Academic Role
Prior to his current role, Frederic Reu was an Associate Professor at the USF Morsani College of Medicine. He worked at the USF Morsani Center for Advanced Health Care from 2020 to 2021. His academic position involved teaching and mentoring medical students and residents in the field of medicine.
Professional Experience in Oncology
Frederic Reu has extensive experience in oncology, having worked as a Senior Director in Early Clinical Development at Bristol Myers Squibb from 2017 to 2020. He also served as an Associate Member at the H. Lee Moffitt Cancer Center and Research Institute from 2020 to 2021. His background includes significant roles in clinical development and patient care in hematologic oncology.
Educational Background
Frederic Reu completed his Doctor of Medicine (MD) at the University of Tübingen, Germany, from 1990 to 1998. He furthered his education at the Cleveland Clinic, where he completed an Internal Medicine Residency and a Medical Oncology Fellowship in the ABMI Research Track, achieving qualifications in Internal Medicine and Medical Oncology between 2000 and 2006.
International Experience
Frederic Reu has international experience in the field of hematologic oncology. He worked as a Physician in Hematologic Oncology at the University of Heidelberg from 2006 to 2008. This role contributed to his expertise in treating blood cancers and enhanced his understanding of global oncology practices.